



Rheonix Receives Additional \$233K Award from National Institutes of Health**

Ithaca, N.Y. — August 17, 2010 — Rheonix, Inc. today announced that the National Institutes of Health has added a \$233,044 supplement to its previously awarded Point-of-Care Partnership grant. The POC Partnership grant is funded to develop a fully automated molecular diagnostic for the detection of multiple sexually transmitted infections (STI). The supplement, awarded under the American Recovery and Reinvestment Act (ARRA) of 2009, was added to expand the scope of efforts to also include the molecular detection of urinary tract infections (UTI).

Tony Eisenhut, Rheonix President, commented, “this competitive awarding of the ARRA supplement further validates our scientific approach as we continue to make excellent progress toward completing a fully automated CARD™ device for the rapid molecular detection of multiple sexually transmitted diseases. Since the original grant was focused on point-of-care testing in nontraditional settings, NIH has recognized the diagnostic value of being able to simply introduce a raw sample and perform all sample preparation, analysis and readout without any user intervention.”

Richard Montagna, Ph.D., Senior Vice President for Scientific Affairs and the project’s Principal Investigator added, “our proprietary low cost production methods will also permit the introduction of these POC devices at very competitive prices, thereby helping to reduce the growing cost of health care.”

About Rheonix, Inc.

Rheonix has created a powerful microfluidic platform for the evolving molecular diagnostics industry. This system incorporates low cost disposable Rheonix CARD™ technology to analyze single or multiple clinical raw samples. The Rheonix CARD system provides multiplexed endpoint analysis and can be rapidly customized for a wide breadth of diagnostic applications. <http://www.rheonix.com/>

Contact:

Rheonix, Inc.
Tony Eisenhut, President
607-257-1242, ext. 160

***The project described was supported by Award Number U01AI082448 from the National Institute of Allergy And Infectious Diseases. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institute of Allergy And Infectious Diseases or the National Institutes of Health.*